These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26539734)

  • 1. How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?
    Novack GD; Moyer ED
    J Ocul Pharmacol Ther; 2016; 32(1):5-10. PubMed ID: 26539734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Jan; 75(13):3471-2. PubMed ID: 20349552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
    Rowe-Rendleman CL
    Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 6. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.
    Haglund J; Halldin MM; Brunnström A; Eklund G; Kautiainen A; Sandholm A; Iverson SL
    Chem Res Toxicol; 2014 Apr; 27(4):601-10. PubMed ID: 24593263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an FDA guidance document for clinical trials in SLE.
    Siegel JN
    Lupus; 1999; 8(8):581-5. PubMed ID: 10568893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of excipients--a Food and Drug Administration perspective.
    Osterberg RE; See NA
    Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICH S9: Developing anticancer drugs, one year later.
    Ponce R
    Toxicol Pathol; 2011 Oct; 39(6):913-5. PubMed ID: 21859887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development and nonclinical to clinical translational databases: past and current efforts.
    Monticello TM
    Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.